[go: up one dir, main page]

GT201000131A - Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/ bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) - Google Patents

Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/ bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)

Info

Publication number
GT201000131A
GT201000131A GT201000131A GT201000131A GT201000131A GT 201000131 A GT201000131 A GT 201000131A GT 201000131 A GT201000131 A GT 201000131A GT 201000131 A GT201000131 A GT 201000131A GT 201000131 A GT201000131 A GT 201000131A
Authority
GT
Guatemala
Prior art keywords
arb
nep
antagonist
inhibitor
pharmaceutical compositions
Prior art date
Application number
GT201000131A
Other languages
English (en)
Inventor
Al-Fayoumi Suliman
Hu Jiahui
Kumaraperumal Natrajan
Royce Alan Edward
Ruegger Colleen
Zannou Erika Aina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201000131(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201000131A publication Critical patent/GT201000131A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS DE ACCIÓN DOBLE BASADAS EN SUPER-ESTRUCTURAS DE ANTAGONISTA/BLOQUEADOR DEL RECEPTOR DE ANGIOTENSINA (ARB) E INHIBIDOR DE ENDOPEPTIDASA NEUTRA (NEP) POR LO QUE SON DE UTILIDAD EN CUADROS DE HIPERTENSIÓN CONSIDERANDO QUE REGULAN DICHOS CUADROS A NIVEL RENAL.
GT201000131A 2007-11-06 2010-05-05 Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/ bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) GT201000131A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
GT201000131A true GT201000131A (es) 2012-04-30

Family

ID=40451030

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000131A GT201000131A (es) 2007-11-06 2010-05-05 Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/ bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)

Country Status (33)

Country Link
US (3) US20100267786A1 (es)
EP (4) EP4186491A1 (es)
JP (2) JP5653218B2 (es)
KR (2) KR101589317B1 (es)
CN (2) CN101848700A (es)
AR (1) AR069184A1 (es)
AU (1) AU2008324878B2 (es)
BR (1) BRPI0823505A2 (es)
CA (1) CA2703598C (es)
CL (1) CL2008003298A1 (es)
CY (2) CY1116280T1 (es)
DK (3) DK2217205T3 (es)
EC (1) ECSP10010160A (es)
ES (3) ES2587336T3 (es)
FI (1) FI3067043T3 (es)
GT (1) GT201000131A (es)
HR (3) HRP20230178T3 (es)
HU (2) HUE061321T2 (es)
IL (3) IL262990B2 (es)
JO (1) JOP20080499B1 (es)
MA (1) MA31797B1 (es)
MX (1) MX2010004930A (es)
MY (1) MY153730A (es)
NZ (1) NZ584686A (es)
PE (2) PE20141072A1 (es)
PL (3) PL3067043T3 (es)
PT (3) PT2295035T (es)
RU (1) RU2493844C3 (es)
SG (1) SG185951A1 (es)
SI (3) SI2217205T1 (es)
TN (1) TN2010000200A1 (es)
TW (1) TWI484982B (es)
WO (1) WO2009061713A1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ584686A (en) 2007-11-06 2013-03-28 Novartis Ag Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
BR112013004192A2 (pt) * 2010-08-24 2016-05-10 Novartis Ag tratamento de hipertensão e/ou prevenção ou tratamento de falha do coração em um mamífero que recebe terapia de anticoagulante
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
CA2882771C (en) * 2012-08-24 2021-02-23 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
AU2014216417B2 (en) 2013-02-14 2016-05-12 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
EA028583B1 (ru) 2013-02-14 2017-12-29 Новартис Аг Замещенные бис-фенилбутановые производные фосфоновой кислоты в качестве ингибиторов nep (нейтральная эндопептидаза)
EP3038653A1 (en) * 2013-08-26 2016-07-06 Novartis AG New use
RS59816B1 (sr) 2013-08-26 2020-02-28 Novartis Ag Nova primena
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
CN110938042B (zh) 2014-12-08 2022-12-13 苏州晶云药物科技股份有限公司 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
SI3294283T1 (sl) 2015-05-11 2023-07-31 Novartis Ag Režim odmerjanja sakubitril-valsartan za zdravljenje srčnega popuščanja
JP2018516267A (ja) 2015-05-29 2018-06-21 ノバルティス アーゲー 代謝性疾患を治療するためのサクビトリルおよびバルサルタン
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017020841A1 (zh) * 2015-08-03 2017-02-09 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
US10596151B2 (en) 2015-08-28 2020-03-24 Novartis Ag Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
PT3411021T (pt) * 2016-02-03 2025-08-06 Novartis Ag Nova utilização de uma combinação de sacubitril e valsartan
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
ES2890573T3 (es) * 2017-03-31 2022-01-20 Tiefenbacher Alfred E Gmbh & Co Kg Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
ES2881317T3 (es) 2017-07-28 2021-11-29 Synthon Bv Composición farmacéutica que comprende sacubitrilo y valsartán
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
WO2019246503A1 (en) 2018-06-22 2019-12-26 Ideaz, Llc Diphenyl tablets and methods of preparing the same
KR20210032437A (ko) 2018-08-23 2021-03-24 노파르티스 아게 심부전의 치료를 위한 신규한 약제학적 용도
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US607893A (en) 1898-07-26 Automatic switch-operating machine
US607355A (en) 1898-07-12 Carrier for bicycles
US608220A (en) 1898-08-02 Mechanical movement
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
HUP0004407A3 (en) * 1997-11-17 2002-03-28 Smithkline Beecham Corp Immediate and modified release oral dosage formulations containing eprosartan and processes for their manufacture
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
DE69926750T2 (de) 1998-06-17 2006-06-29 Bristol-Myers Squibb Co. Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
ID29856A (id) * 1998-12-23 2001-10-18 Novartis Ag Penggunaan antagonis reseptor at-1 atau modulator reseptor at-2 untuk mengobati penyakit yang berkaitan dengan peningkatan reseptor-reseptor at-1 atau at-2
MXPA03000525A (es) 2000-07-19 2003-05-14 Novartis Ag Sales de valsartan.
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
IL162661A0 (en) * 2002-01-17 2005-11-20 Novartis Ag Pharmaceutical compositions comprising valsartan and nep inhibitors
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
WO2003089417A1 (en) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
EP1648515B1 (en) * 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
AU2006307470A1 (en) * 2005-10-27 2007-05-03 Lupin Limited Pharmaceutical formulation of losartan
WO2007052307A2 (en) 2005-10-31 2007-05-10 Lupin Limited Stable solid oral dosage forms of valsartan
US8689376B2 (en) 2005-11-07 2014-04-08 Stryker Corporation Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration
US20080261958A1 (en) 2005-11-08 2008-10-23 Randy Lee Webb Combination of Organic Compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
NZ584686A (en) 2007-11-06 2013-03-28 Novartis Ag Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate

Also Published As

Publication number Publication date
KR101589317B9 (ko) 2022-11-23
PE20141072A1 (es) 2014-09-10
IL262990A (en) 2018-12-31
EP3067043B1 (en) 2022-11-30
SI2295035T1 (sl) 2016-09-30
HK1149721A1 (en) 2011-10-14
ES2536514T3 (es) 2015-05-26
EP2217205B1 (en) 2015-03-04
KR101589317B1 (ko) 2016-01-28
ES2939163T3 (es) 2023-04-19
DK3067043T3 (da) 2023-02-27
CL2008003298A1 (es) 2009-06-26
JOP20080499B1 (ar) 2022-09-15
US20210085631A1 (en) 2021-03-25
SI2217205T1 (sl) 2015-10-30
FI3067043T3 (fi) 2023-03-18
PT2295035T (pt) 2016-08-22
IL249922A0 (en) 2017-03-30
NZ584686A (en) 2013-03-28
HRP20160988T1 (hr) 2016-10-07
DK2217205T3 (en) 2015-05-11
IL205208A0 (en) 2010-12-30
AR069184A1 (es) 2010-01-06
SG185951A1 (en) 2012-12-28
EP2295035A3 (en) 2012-08-08
HUE028866T2 (en) 2017-01-30
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
CA2703598A1 (en) 2009-05-14
WO2009061713A1 (en) 2009-05-14
PL3067043T3 (pl) 2023-05-08
KR20100085087A (ko) 2010-07-28
EP2295035A2 (en) 2011-03-16
SI3067043T1 (sl) 2023-04-28
MY153730A (en) 2015-03-13
PE20091390A1 (es) 2009-10-13
ECSP10010160A (es) 2010-06-29
AU2008324878A1 (en) 2009-05-14
JP2011503082A (ja) 2011-01-27
PL2295035T3 (pl) 2016-11-30
CN103251587A (zh) 2013-08-21
EP2217205A1 (en) 2010-08-18
BRPI0823505A2 (pt) 2015-06-16
US20100267786A1 (en) 2010-10-21
CA2703598C (en) 2016-08-09
HRP20230178T3 (hr) 2023-03-31
HK1143529A1 (en) 2011-01-07
PT2217205E (pt) 2015-06-08
CY1116280T1 (el) 2017-03-15
IL205208A (en) 2017-01-31
EP3067043A1 (en) 2016-09-14
TW200936183A (en) 2009-09-01
KR101700062B1 (ko) 2017-01-26
JP5653218B2 (ja) 2015-01-14
PT3067043T (pt) 2023-03-01
IL262990B2 (en) 2023-10-01
MX2010004930A (es) 2010-05-27
AU2008324878B2 (en) 2013-04-18
ES2587336T3 (es) 2016-10-24
HK1224195A1 (en) 2017-08-18
KR20150139624A (ko) 2015-12-11
IL262990B1 (en) 2023-06-01
TN2010000200A1 (en) 2011-11-11
CN101848700A (zh) 2010-09-29
PL2217205T3 (pl) 2015-07-31
TWI484982B (zh) 2015-05-21
HRP20150459T1 (hr) 2015-07-17
JP2015038069A (ja) 2015-02-26
EP4186491A1 (en) 2023-05-31
KR101700062B9 (ko) 2022-11-23
RU2010123027A (ru) 2011-12-20
MA31797B1 (fr) 2010-10-01
CY1117883T1 (el) 2017-05-17
DK2295035T3 (en) 2016-08-29
EP2295035B1 (en) 2016-05-18
HUE061321T2 (hu) 2023-06-28
RU2493844C2 (ru) 2013-09-27

Similar Documents

Publication Publication Date Title
GT201000131A (es) Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/ bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)
ECSP14019136A (es) Combinaciones farmacéuticas de un antagonista del receptor de angiotensina y un inhibidor de endopeptidasa neutra (nep)
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CL2012000800A1 (es) Uso de una cantidad de un anticuerpo antagonista de notch3 especifico para tratar leucemia de celulas t sensibles a inhibidores gama secretasa (gsi) que no responde a un antagonista de notch1 especifico, en un paciente con leucemia.
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
ATE469895T1 (de) Cgrp-rezeptorantagonisten
GT201300196A (es) Moduladores del receptor de glucagón
SV2009003221A (es) Composiciones de fenilalquilamino carbamato ref. prd2743svpct
ECSP099225A (es) Compuestos antagonistas del receptor de glucagón, composiciones que contienen dichos compuestos y procedimientos de uso
FR2936320B1 (fr) Traitement de signaux de radionavigation utilisant une combinaison widelane
BRPI0919291A2 (pt) película parcialmente metalizada que tem propriedades de barreira.
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
WO2011033064A3 (en) Disulfo-type fluorescent whitening agent compositions
CR9934A (es) Composiciones de asilamiento libres de plomo mejoradas que contienen polimeros de metaloceno
AR075064A1 (es) Composiciones de alto contenido de ion fluoruro recuperado
CL2008003266A1 (es) Compuestos derivados de pirimidindiona y triazindiona sustituidas con cicloguanidina, utiles como antagonista del receptor de procineticina; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades gastrointestinales.
CL2008000091A1 (es) Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria.
CL2007003613A1 (es) Compuestos nitroderivados, antagonistas del receptor de angiotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension.
GT200600411A (es) Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
EA201390603A1 (ru) Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
EA201290851A1 (ru) Способы и композиции для лечения или предупреждения симптомов гормональных изменений
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
TR200903014A1 (tr) Oral yolla dağılan dimebolin bileşimleri.
FR2913338B1 (fr) Composition de rehydratation.
CL2007001937A1 (es) Compuestos derivados de bencilsulfanilpiridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de agregacion plaquetaria.